GENE ONLINE|News &
Opinion
Blog

2022-03-16| Trials & Approvals

Merck Breaks Off Keytruda Combo Trial with AstraZeneca, Begins Another with Imugene

by Joy Lin
Share To

Merck (known as MSD outside the United States and Canada) and partner AstraZeneca have ditched a Phase 3 combination trial of Keytruda and Lynparza in metastatic castration-resistant prostate cancer (mCRPC). The same day, Merck revealed a new clinical trial collaboration with Australia-based Imugene that would test a combination of Keytruda and Imugene’s HER-Vaxx against HER-2 positive gastric or gastroesophageal junction adenocarcinomas.   

 

Keytruda/Lynparza Did Not Improve Overall Survival Versus Control

 

Merck and AstraZeneca had jointly worked together to develop Lynparza (olaparib), a PARP inhibitor. By inhibiting PARP which is an essential enzyme in DNA repair, Lynparza had the potential to act against ovarian, breast and prostate cancer. The drug received its first FDA approval for BRCA-mutated HER2-negative breast cancer.

Merck’s Tuesday decision to stop the Phase 3 Keylink-010 Keytruda/ Lynparza trial for mCRPC followed a recommendation from an independent data monitoring committee (DMC). 

In an interim analysis reviewed by the DMC, Keytruda/ Lynparza failed to show benefit in overall survival compared to the control groups of abiraterone acetate or enzalutamide. 

An earlier interim readout showed that the study did not meet the other primary endpoint, radiographic progression-free survival (rPFS), after the combo did not demonstrate improvement compared to control. 

Related Article: Recent Advances in Breast Cancer Treatments: An Overview

 

Keytruda/HER-Vaxx for Gastric Cancer  

 

In a separate development, Merck and Imugene will begin a Phase 2 trial dubbed nextHERizon investigating Keytruda/ HER-Vaxx in patients with HER-2 positive gastric cancer that have failed trastuzumab. 

HER-Vaxx is a B-cell activating cancer vaccine, designed to train B-cells to recognize cancer cells that over express HER-2. It is constructed from several B epitopes, or antigens, derived from the extracellular domain of HER-2.  According to Imugene CEO Leslie Chong, the drug shows a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and will be tested in the relapsed/ refractory/ metastatic setting. 

Imugene will fund the study, while Keytruda will be provided by Merck during the trial, which is expected to last at least 24 months. 

Related Article Merck’s Keytruda Bags FDA Approval for Early Kidney Cancer in Adjuvant Setting

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Blesses Merck’s Pneumococcal Vaccine for Pediatric Use
2022-06-23
Valneva Receives Funding From Pfizer to Develop World’s Only Lyme Disease Vaccine
2022-06-21
Why CRY2 matters: Studying Control of Plants and Human Growth
2022-06-20
LATEST
Blueprint Medicines Gathers Up To $1.25 Billion in Loans and Investments for Research and Development
2022-07-01
FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment
2022-07-01
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
Bon Natural Life Limited Announces Change to Board Composition
2022-06-30
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
ReCode Therapeutics’ Secures an Extra $120 Million To Support Its Drug Delivery Platform
2022-06-30
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top